Healthcare company Baxter International (NYSE:BAX) in Q3 CY2025, but sales rose 5% year on year to $2.84 billion. Next quarter’s revenue guidance of $2.81 billion underwhelmed, coming in 6.5% below ...
Healthcare company Baxter International (NYSE:BAX) reported Q4 CY2025 results , with sales up 8% year on year to $2.97 billion. Its non-GAAP profit of $0.44 per share was 17.8% below analysts’ ...
In recent days, Baxter International has faced renewed legal scrutiny as law firms announced investigations into alleged governance failures, product safety misstatements around its Novum LVP infusion ...
NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Baxter International, Inc. (NYSE: BAX). Shareholders who purchased shares of BAX during the ...
Baxter stock (NYSE: BAX), a healthcare company, has seen its stock decline by 14% over the past month. This drop followed a disappointing earnings report where the company also reduced its full-year ...
LOS ANGELES-- (BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results